

Mouse CCL2/JE/MCP-1 Antibody

Polyclonal Goat IgG Catalog Number: AB-479-NA


DESCRIPTION			
Species Reactivity	Mouse		
Specificity	Detects mouse CCL2/JE/MCP-1 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant human MCP-1, recombinant mouse (rm MCP-5, and recombinant rat JE is observed. In Western blots, no cross-reactivity with rmEotaxin, rmMCP-5, or rmCCL7 is observed.		
Source	Polyclonal Goat IgG		
Purification	Protein A or G purified		
Immunogen	E. coli-derived recombinant mouse CCL2/JE/MCP-1 Gln24-Arg96 Accession # Q5SVU3		
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.		

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	1 μg/mL	See Below
Neutralization	Measured by its ability to neutralize CCL2/JE/MCP-1-induced chemotaxis in the BaF3 mouse pro-B cell line transfected with human CCR2A. The Neutralization Dose (ND ₅₀) is typically 10-30 μg/mL in the presence of 40 ng/ml. Recombinant Mouse CCI 2/JE/MCP-1	


DATA



Detection of Recombinant Mouse CCL2/JE/MCP-1 by Western Blot.

Western blot shows 25 ng of Recombinant Mouse CCL2/JE/MCP-1 (Catalog # 479-JE), Recombinant Human CCL2/JE/MCP-1 (Catalog # 279-MC), Recombinant Rat CCL2/JE/MCP-1 (Catalog # 3144-JE), Recombinant Mouse CCL11/Eotaxin (Catalog # 420-ME), Recombinant Mouse CCL12/MCP-5 (Catalog # 428-P5), and Recombinant Mouse CCL7/MCP-3/MARC (Catalog # 456-MC), PVDF Membrane was probed with 1 µg/mL of Goat Anti-Mouse CCL2/JE/MCP-1 Polyclonal Antibody (Catalog # AB-479-NA) followed by HRPconjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for CCL2/JE/MCP-1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer

Neutralization



Chemotaxis Induced by CCL2/JE/MCP-1 and Neutralization by Mouse CCL2/JE Antibody. Recombinant Mouse

CCL2/JE (Catalog # 479-JE) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR2A in a dosedependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002) Chemotaxis elicited by Recombinant Mouse CCL2/JE (40 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse CCL2/JE/MCP-1 Polyclonal Antibody (Catalog # AB-479-NA). The $\overline{\text{ND}}_{50}$ is

typically 10-30 µg/mL.

PREPARATION AND STORAGE

 Reconstitution
 Reconstitute at 1 mg/mL in sterile PBS.

 Shipping
 The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Mouse CCL2 is a member of the β (C-C) subfamily of chemokines. The murine CCL2 gene was initially identified as a platelet-derived growth factor-inducible gene in murine fibroblasts. Mouse CCL2 cDNA encodes a 148 amino acid (aa) residue with a putative 23 aa signal peptide that is cleaved to generate the mature protein. Mouse CCL2 shares 82% amino acid sequence identity with rat CCL2. Mouse CCL2 also shares 55% amino acid sequence identity with human MCP-1. Compared to human MCP-1, mouse CCL2 has a 49 aa residue extension at the carboxy-terminus. Mouse CCL2 has full activity on human cells while human MCP-1 has limited activity on mouse cells.

References:

- 1. Rollins, B.J. et al. (1988) Proc. Natl. Acad. Sci. USA 85:3738.
- 2. Gu, L. et al. (1999) Chem. Immunol. 72:7.
- 3. Luini, W. et al. (1994) Cytokine 6:28.

Rev. 2/6/2018 Page 1 of 1

